Therefore, efforts were made to activate this signaling using, for instance, STING agonists in clinical trials, though not (yet) specifically for CIN+ cancers (Le Naour et al. 2020). This evidence concerns the gene STING1 and cervical squamous intraepithelial neoplasia.